Acne

A post-AAD 2024 discussion on the importance of tailoring acne and rosacea management to individual patients’ needs, focusing more attention on diverse skin types and backgrounds.

The AAD's Acne Management Guidelines include updates to the recommendations for treating acne and aims to assist clinicians and patients in making informed decisions on acne management. Test your knowledge with this quiz.

In recognition of the Pre-AAD 2024 meeting, take our quiz based on Society for Pediatric Dermatology resources.

This analysis concluded that the carcinogen known as benzene can be broadly found in concerning levels within benzoyl peroxide (BPO) acne treatment products.

Additional research on this form of moisturizer and other ingredients for acne with larger sample sizes may be needed to verify efficacy for acne vulgaris.

In new guidelines by the AAD, 18 new evidence-based recommendations and 5 practice statements were described for patients 9 years of age and older with acne.

These findings highlight the real access barriers faced by TGD individuals as well as the necessity of additional research to promote evidence-based hormonal acne treatments.

Given the lack of widespread awareness of the magnitude and prevalence of the public’s stigma toward people with acne, this research sought to expand upon this body of research.

This new data highlights the value of proper counseling regarding possible adverse effects prior to initiation of treatment initiation with JAK inhibitors.

Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.

Given that this new research was an exploratory study with a smaller sample size, the study’s results may not be generalized and future studies should use more patients and institutions.

This new research letter highlights several trends in prescribing by both dermatologists and non-dermatologists from 2017 to 2020.

This new data from China showed that both the duration of mask-wearing and greater use of facial cleansing may result in skin deterioration, though moisturizing products were found to have more positive effects.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.

From addressing the rare acne fulminans to utilizing narrow-spectrum antibiotics, the modern field of acne treatment is more complicated than it seems.

In the span of a decade, agents like topical ivermectin, minocycline and benzoyl peroxide has provided more opportunities to achieve clear skin for rosacea patients.

Yan discusses how acne care strategies have been bolstered—and complicated—by pharmacotherapy and telemedicine developments.

This study evaluated tranexamic acid injection for post-acne vulgaris erythema, though its smaller sample size may require the findings to be reproduced in large-scale studies.

A new study in China showed that a combination of mask and serum containing both salicylic acid and lipohydroxy acid showed improvement in acne.

A recent analysis showed that a combination treatment made of phosphate, adapalene, and benzoyl peroxide known as IDP-126 was well-tolerated and effective in pediatric participants with acne.

New data from a systematic literature review highlighted the connection with tumor necrosis factor-α inhibitors and acne, indicating the need for further study.

Recent data highlighted the relationship between different blood types and acne severity, identifying correlations between specific groups.

In another segment of her interview with HCPLive, Graber explored some of the latest treatment developments for acne and rosacea covered in her 2023 Winter Clinical Miami presentation.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

Phase 3 data suggest the novel twice-daily drug provides favorable efficacy and consistent safety over a regular regimen in patients aged 12 years and older.

Patients over 21 years who developed acne presented with different clinical characteristics than younger patients.

The COVID-19 pandemic has drawn attention to acne associated with the prolonged use of medical face masks and raised awareness about the need for adequate screening, training and treatment of the condition.

New phase 3 data show a microencapsulated form of the topical antiseptic and vitamin D derivative is beneficial and tolerable over 12 weeks.